Therapeutic proteins are often immunogenic, inducing anaphylactic reactions and/or specific immunoglobulins. Their administration is often stopped or inefficient due to neutralizing antibodies. ERYTECH’s concept consists in encapsulating the therapeutic proteins inside erythrocytes. The membrane of the erythrocytes is modified to target the immune cells known to induce tolerance. ERYTECH’s researchers demonstrated this concept with different proteins. The reduction of specific antibody TITER was strong and maintained for months.

"This novel approach is very promising. This would allow patients to receive their treatment longer with a sustained efficacy. The red cells are very well adapted carriers, because they can naturally target the cells of immunity" explained Dr Godfrin.

ERYTECH Pharma SA is a late-stage French biopharmaceutical company developing medicinal products for oncology and rare diseases. The company's patented core technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes (eg asparaginase). ERYTECH's lead product, GRASPA® for the treatment of Acute Lymphoblastic Leukemia (ALL), holds orphan designation in Europe and the US an is in a pivotal Phase II/III clinical trial in Europe.

www.erytech.com  

ERYTECH Pharma, 60 Avenue Rockefeller, Bâtiment Adénine, F-69008 Lyon, France

ERYTECH Pharma (US Office), 3711 Market Street, 19104 Philadelphia PA, USA

ALIZE RP

Caroline Carmagnol

+33 142 688 643 // +33 664 189 959

caroline@alizerp.com